The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy

Immune checkpoint blockade therapy can elicit robust and durable responses in a variety of cancer types. While many patients do not respond, recent reports highlight a distinct group of patients whose tumors undergo rapid growth, leading to progressive disease and poor outcome. In this perspective,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabio, Erich, Chan, Timothy A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6651948/
https://www.ncbi.nlm.nih.gov/pubmed/31340855
http://dx.doi.org/10.1186/s13073-019-0661-7
_version_ 1783438463190695936
author Sabio, Erich
Chan, Timothy A.
author_facet Sabio, Erich
Chan, Timothy A.
author_sort Sabio, Erich
collection PubMed
description Immune checkpoint blockade therapy can elicit robust and durable responses in a variety of cancer types. While many patients do not respond, recent reports highlight a distinct group of patients whose tumors undergo rapid growth, leading to progressive disease and poor outcome. In this perspective, we synthesize and summarize some important issues surrounding hyperprogression, defining characteristics, prognostic implications, and controversies.
format Online
Article
Text
id pubmed-6651948
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66519482019-07-31 The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy Sabio, Erich Chan, Timothy A. Genome Med Comment Immune checkpoint blockade therapy can elicit robust and durable responses in a variety of cancer types. While many patients do not respond, recent reports highlight a distinct group of patients whose tumors undergo rapid growth, leading to progressive disease and poor outcome. In this perspective, we synthesize and summarize some important issues surrounding hyperprogression, defining characteristics, prognostic implications, and controversies. BioMed Central 2019-07-24 /pmc/articles/PMC6651948/ /pubmed/31340855 http://dx.doi.org/10.1186/s13073-019-0661-7 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Comment
Sabio, Erich
Chan, Timothy A.
The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy
title The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy
title_full The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy
title_fullStr The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy
title_full_unstemmed The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy
title_short The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy
title_sort good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6651948/
https://www.ncbi.nlm.nih.gov/pubmed/31340855
http://dx.doi.org/10.1186/s13073-019-0661-7
work_keys_str_mv AT sabioerich thegoodthebadandtheuglyhyperprogressionincancerpatientsfollowingimmunecheckpointtherapy
AT chantimothya thegoodthebadandtheuglyhyperprogressionincancerpatientsfollowingimmunecheckpointtherapy
AT sabioerich goodthebadandtheuglyhyperprogressionincancerpatientsfollowingimmunecheckpointtherapy
AT chantimothya goodthebadandtheuglyhyperprogressionincancerpatientsfollowingimmunecheckpointtherapy

Ejemplares similares